Добавил:
Sekretar
kiopkiopkiop18@yandex.ru
t.me/Prokururor I Вовсе не секретарь, но почту проверяю
Опубликованный материал нарушает ваши авторские права? Сообщите нам.
Вуз:
Предмет:
Файл:Ординатура / Хирургия / Библиотека им академика М.И. Перельмана / Книга_5529_Библиотеки_им_академика_М_И_Перельмана
.pdf
54 Bioinformatics of Autoimmune Diseases
of sequences that should normally be removed. These retained introns often contain premature stop
codons or destabilizing elements that impair protein translation or mRNA stability.
Although alternative splicing is a natural mechanism that contributes to proteomic diversity,
particularly during development and in tissue-specic gene expression, aberrant splicing due to
mutations represents a signicant pathogenic mechanism. In autoimmune diseases, altered splicing
patterns may affect key immune regulators or structural proteins, thereby compromising immune
tolerance and enhancing inammation.
Splicing mutations play a signicant role in the pathogenesis of autoimmune diseases by disrupting immune tolerance, altering antigen presentation, and enabling uncontrolled inammatory
responses. One of the most well-characterized cases involves the AIRE (autoimmune regulator)
gene, which is essential for the expression of peripheral tissue antigens in the thymus and the deletion of self-reactive T cells during central tolerance. Mutations that affect the splicing of the AIRE
transcript (such as those causing exon skipping or the introduction of premature stop codons) can
result in the production of dysfunctional AIRE protein. This failure to eliminate autoreactive T cells
leads to the development of autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy
(APECED), a rare monogenic autoimmune disorder characterized by multi-organ autoimmunity,
chronic mucocutaneous candidiasis, and ectodermal abnormalities.
Another critical example is the FOXP3 gene, which encodes a transcription factor that is indispensable for the development and function of regulatory T cells (Tregs). These cells act as key
suppressors of autoreactive immune responses, maintaining immune homeostasis and preventing
excessive inammation. Splicing mutations in FOXP3 (particularly those that lead to exon loss or
truncated protein products) can result in the production of nonfunctional FOXP3 proteins. The loss
of Treg-mediated immunosuppression contributes to immune dysregulation, polyendocrinopathy,
enteropathy, X-linked (IPEX) syndrome, a severe autoimmune condition that emerges early in life
and presents with life-threatening symptoms such as severe enteropathy, T1D, eczema, and autoimmune thyroiditis (Bennett etal., 2001).
These examples highlight how disruption of precise RNA splicing can derail central and peripheral immune tolerance mechanisms, ultimately triggering systemic autoimmunity. By compromising the expression of key regulatory proteins, splicing mutations in genes like AIRE and FOXP3 not
only deepen our understanding of autoimmune disease mechanisms but also point toward potential
diagnostic and therapeutic targets.
Table 2.6 presents several gene splicing mutations associated with autoimmune diseases and
their potential impacts.
TABLE 2.6
Examples of Splicing Mutations and Impacts
Variant Splicing Associated Autoimmune
Reference ID Gene Mutation Impact Disease(s)
rs121434258 AIRE Splice-site Defective immune tolerance, failure Autoimmune polyendocrinopathy-
mutation to eliminate autoreactive T cells candidiasis-ectodermal dystrophy
(APECED)
rs750491098 FOXP3 Exon skipping Disrupts regulatory T-cell function, Immune dysregulation,
leading to autoimmunity polyendocrinopathy, enteropathy,
X-linked (IPEX) syndrome
rs733618 CTLA4 Splicing defect Reduces immune checkpoint function, SLE, RA
promoting excessive T-cell activation
rs200820567 TNFAIP3 Splice-site
disruption
Causes dysregulated NF-κB
signaling, leading to chronic
inammation
RA, SLE
55 Genetic Markers in Autoimmunity
Splicing mutations have also been implicated in the dysregulation of immune checkpoint
pathways, particularly in genes like CTLA4, which encodes a critical co-inhibitory receptor
on T cells. CTLA-4 functions as a regulatory brake on immune activation, helping to prevent
autoimmunity. When splicing mutations impair the production or function of CTLA-4, the
result is a state of CTLA4 haploinsufciency, a condition that diminishes immune restraint and
promotes chronic inammation. This genetic defect has been linked to several autoimmune
conditions, including RA, SLE, and common variable immunodeciency (CVID) (Schubert
etal., 2014).
Another notable example is TNFAIP3 (A20), a key negative regulator of the NF-κB signaling pathway, which normally functions to suppress inammatory responses. Splicing errors in
TNFAIP3 can lead to reduced expression or dysfunctional A20 protein, removing a critical layer of
immune control. The loss of this regulation results in sustained inammatory signaling, which has
been associated with autoimmune diseases such as RA and lupus (Zhou etal., 2016).
Advances in RNA sequencing technologies have further expanded our understanding of splicing
defects in autoimmunity. These high-resolution methods have revealed numerous splicing mutations
in genes involved in cytokine signaling, T-cell differentiation, and antigen recognition, reinforcing
the role of alternative splicing as a key mechanism in autoimmune disease pathogenesis.
Given the importance of splicing delity in immune regulation, RNA-targeted therapies are
being actively explored. Strategies such as antisense oligonucleotides (ASOs) and small-molecule
splicing modulators aim to restore proper splicing patterns in affected genes. These therapeutic
innovations offer new hope for treating autoimmune diseases at their genetic and transcriptomic
roots and represent a promising frontier in precision medicine.
2.3 EPIGENETIC CHANGES
Epigenetic modications are heritable but reversible changes in gene expression that occur
without altering the underlying DNA sequence. These modications regulate how genes are
activated or silenced and include mechanisms such as DNA methylation, histone modications, and non-coding RNA (ncRNA)-mediated regulation. In contrast to genetic mutations,
which involve permanent changes in nucleotide sequences, epigenetic changes are dynamic and
often responsive to environmental stimuli such as infections, stress, diet, or chemical exposure
(Feinberg, 2018). When these regulatory processes are disrupted, they can lead to aberrant
immune activation, loss of self-tolerance, and chronic inammation—hallmarks of autoimmune pathogenesis.
Among the most extensively studied epigenetic mechanisms in autoimmunity is DNA methylation, which typically occurs at CpG dinucleotides and serves to silence gene expression in a tissuespecic and context-dependent manner. In healthy immune systems, DNA methylation ensures
that immune-related genes are tightly regulated. However, in autoimmune conditions such as SLE,
global and gene-specic hypomethylation has been consistently observed. For instance, hypomethylation of the CD40L gene in T cells from lupus patients leads to its overexpression, promoting
B-cell activation and autoantibody production (Lu etal., 2007).
Similarly, in RA, decreased methylation of promoter regions for pro-inammatory cytokine
genes such as TNF-α and IL-6 results in sustained transcriptional activation and chronic joint
inammation. These methylation abnormalities contribute not only to disease initiation but also to
its persistence and severity, further implicating epigenetic dysregulation as a critical layer in autoimmune disease pathophysiology.
Figure 2.4 illustrates the process of DNA methylation, a key epigenetic modication involving
the addition of a methyl group (CH3) to the cytosine base within the DNA double helix. Specically,
methylation typically occurs at cytosine residues in CpG dinucleotides, where a cytosine is followed by a guanine in the DNA sequence. The diagram shows a methyl group being transferred to
the cytosine ring, catalyzed by DNA methyltransferase enzymes (DNMTs), which are represented
56 Bioinformatics of Autoimmune Diseases
FIGURE 2.4 DNA methylation.
here as the cloud-shaped enzyme. This modication can alter gene expression without changing the
underlying DNA sequence, often leading to gene silencing when present in promoter regions. DNA
methylation plays a critical role in cellular differentiation, X-chromosome inactivation, genomic
imprinting, and the suppression of transposable elements, and is also implicated in various diseases,
including cancer and autoimmune disorders.
Beyond DNA methylation, histone modications are key epigenetic mechanisms that shape
immune cell behavior and gene expression. Histones are structural proteins around which DNA
is tightly coiled, and their chemical modication (through processes such as acetylation, methylation, phosphorylation, and ubiquitination) alters chromatin accessibility and gene transcription. For
example, histone hypoacetylation of genes involved in Treg function has been observed in MS, leading to diminished Treg activity and impaired suppression of self-reactive T cells that target myelin
sheaths. In contrast, histone hyperacetylation of promoters for pro-inammatory cytokines such as
IL-6 and TNF-α in IBD enhances their transcription, driving chronic inammation in intestinal
tissues.
Complementing histone-mediated regulation, ncRNAs, particularly microRNAs (miRNAs)
and long lncRNAs, serve as potent post-transcriptional modulators of gene expression. miRNAs
function primarily by binding to complementary sequences in mRNA transcripts, leading to translational repression or mRNA degradation. In autoimmune diseases, dysregulation of miRNAs contributes to immune imbalance. For instance, miR-146a, which normally dampens inammation by
targeting TRAF6 and IRAK1 in the NF-κB pathway, is signicantly downregulated in SLE and
RA, resulting in amplied inammatory signaling (Tang etal., 2009). On the other hand, miR-155,
known for its pro-inammatory effects, is overexpressed in MS and SLE, promoting excessive
T-cell activation and cytokine production.
Unlike genetic mutations, epigenetic alterations are reversible and highly responsive to environmental inputs, including infection, stress, and nutrition. This dynamic nature not only underscores
their role in autoimmune pathogenesis but also highlights their therapeutic potential. Epigenetic
therapies such as DNA methyltransferase inhibitors, histone deacetylase (HDAC) inhibitors, and
miRNA-based interventions are currently under investigation for their ability to reprogram aberrant
immune responses. For example, HDAC inhibitors have shown efcacy in restoring Treg function
in preclinical models of MS, while synthetic miRNA mimics or antagonists are being developed to
modulate disease-relevant miRNAs.
As our understanding of immune epigenomics expands, targeting histone modications and
ncRNA dysregulation may provide a precise and adaptable strategy for managing autoimmune diseases. The growing toolbox of epigenetic therapies offers promising avenues to correct immune
dysfunction at its regulatory core.
TABLE 2.7
Example of Epigenetic Changes and Their Impacts
Gene/Pathway
Epigenetic Modication Affected Impact
DNA hypomethylation CD40L Increased B-cell activation
and autoantibody production
DNA hypomethylation
Histone hypoacetylation Treg-related genes Reduced regulatory T-cell
Histone hyperacetylation Pro-inammatory Excessive inammatory
miR-146a downregulation
miR-155 overexpression T-cell activation Enhanced immune system
TNF-α, IL-6
cytokines signaling
NF-κB pathway
genes overactivity
Overexpression of
inammatory cytokines
function
Increased immune activation
Associated Autoimmune
Disease(s)
Systemic lupus erythematosus (SLE)
Rheumatoid arthritis (RA)
Multiple sclerosis (MS)
Inammatory bowel disease (IBD)
Systemic lupus erythematosus (SLE),
rheumatoid arthritis (RA)
Multiple sclerosis (MS), systemic
lupus erythematosus (SLE)
Table 2.7 illustrates how some epigenetic changes inuence immune dysregulation in autoim-
mune diseases.
57 Genetic Markers in Autoimmunity
2.4 STRUCTURAL VARIATIONS
Structural variations (SVs) are large-scale genomic alterations encompassing deletions, duplications, inversions, insertions, and translocations. These rearrangements typically involve DNA segments ranging from several kilobases to millions of base pairs and can profoundly affect gene
function, regulatory sequences, and chromosomal architecture. Unlike point mutations or small
indels, SVs often result in gene dosage alterations, position effects, or gene disruption, mechanisms
that are particularly relevant in autoimmune diseases where precise immune regulation is essential.
One of the most studied regions affected by SVs is the HLA locus on chromosome 6. This region
encodes MHC proteins that govern antigen presentation and self–non-self recognition. Deletions or
duplications in HLA-DRB1, for instance, have been strongly associated with autoimmune diseases
such as RA, MS, and T1D. Alterations in HLA gene copy number can change antigen presentation
proles, thus inuencing T-cell responses and tolerance.
Beyond the HLA region, CNVs affecting complement system components are key contributors to
autoimmunity. For example, deletions in C4A and C4B, two genes encoding complement proteins,
impair the immune system’s ability to clear apoptotic debris and immune complexes. This defect
increases the risk for SLE due to chronic activation of the innate immune system and the development of autoantibodies. Similarly, deletions in FCGR3B, a gene involved in Fc receptor-mediated
phagocytosis, reduce the clearance of immune complexes and are associated with heightened risk
for both RA and SLE (Aitman etal., 2006).
Inammatory signaling dysregulation is another critical pathway inuenced by structural variants. Deletions of TNFAIP3 (A20), a gene that acts as a negative regulator of the NF-κB pathway,
result in the loss of feedback control mechanisms that normally suppress excessive inammation.
Mutations or deletions in this gene have been linked to RA, SLE, and IBD, due to the unchecked
activation of immune cells and persistent cytokine production. Conversely, duplications involving
IL17F and IL23R, genes that drive Th17 cell differentiation, have been observed in psoriasis and
Crohn’s disease, where they promote chronic pro-inammatory responses.
Structural variants also disrupt immune checkpoint pathways that regulate T-cell activation.
Deletion of CTLA4, a critical inhibitor of T-cell responses, can lead to hyperactive immune function
58 Bioinformatics of Autoimmune Diseases
TABLE 2.8
Examples of Structural Variants and Their Impacts
Variant Type of
Reference Gene(s) Structural Associated Autoimmune
ID Affected Variation Impact Disease(s)
esv2676146 C4A/C4B Deletion Impaired complement system, Systemic lupus erythematosus
defective immune complex (SLE)
clearance
esv2676147 FCGR3B Deletion Reduced immune complex clearance, Rheumatoid arthritis, SLE
increased inammation
esv1001847 TNFAIP3 Deletion
(A20)
esv2676148 HLA-DRB1 Deletion/ Disrupted antigen presentation, Rheumatoid arthritis, type 1
duplication increased autoimmunity diabetes, multiple sclerosis
nsv834099 IL17F, IL23R Duplication Heightened inammatory cytokine Psoriasis, Crohn’s disease
esv3656789 CTLA4 Deletion Impaired immune checkpoint Rheumatoid arthritis, autoimmune
Loss of NF-κB regulation, excessive
immune activation
activity
function, unregulated T-cell lymphoproliferative syndrome
activation (ALPS)
Rheumatoid arthritis, SLE,
inammatory bowel disease (IBD)
and has been implicated in disorders such as autoimmune lymphoproliferative syndrome (ALPS),
RA, and MS. These examples highlight the broad and multifaceted roles that structural genomic
changes play in shaping the immune landscape and determining autoimmune susceptibility.
Table 2.8 summarizes key SVs and their associations with autoimmune disease development
and severity. Continued efforts in genome sequencing and structural variant annotation promise
to uncover additional SVs that contribute to immune dysfunction, providing new opportunities for
diagnosis and targeted therapies.
2.5 GAIN-OF-FUNCTION MUTATIONS
GOF mutations are genetic alterations that enhance a gene’s activity, confer a novel function, or lead
to its inappropriate expression. Unlike LOF mutations that reduce or abolish gene activity, GOF
mutations often cause hyperactive proteins, constitutive signaling, or altered cellular interactions.
These mutations typically exhibit a dominant inheritance pattern, meaning a single copy of the
altered gene is sufcient to cause disease. GOF effects may include continuous protein activation,
removal of normal regulatory feedback, or enhanced protein stability that contributes to sustained
immune signaling.
In autoimmune diseases, GOF mutations frequently result in exaggerated immune responses
and chronic inammation. A prime example is STAT3 GOF mutations, which lead to persistent
activation of the JAK–STAT pathway. This disrupts the balance between regulatory T cells (Tregs)
and pro-inammatory Th17 cells, favoring an environment of heightened immune activation. These
changes have been implicated in early-onset autoimmunity, including SLE and autoimmune enteropathy (Haapaniemi etal., 2015). Patients often show resistance to immunosuppressive therapies
due to sustained cytokine signaling.
Another important example involves TYK2 GOF mutations, which enhance signaling through
type I interferon (IFN), interleukin-12 (IL-12), and interleukin-23 (IL-23) pathways. These alterations drive excessive inammatory responses, contributing to autoimmune diseases such as MS,
lupus, and psoriasis (Boisson-Dupuis et al., 2018). Similarly, NLRP3 GOF mutations result in
59 Genetic Markers in Autoimmunity
TABLE 2.9
Example of Gain-of-Function Mutations and Their Impacts
Associated Autoimmune
Gene Mutation Description Impact Disease(s)
STAT3 Germline mutations leading to Causes early-onset autoimmunity, STAT3 gain-of-function disease
increased STAT3 activity lymphoproliferation, and multi-organ
inammation
NOD2 Mutations resulting in enhanced Triggers abnormal inammatory Blau syndrome
activation of NOD2 protein responses, affecting skin, eyes, and joints
NLRP1 Variants causing increased Leads to excessive production of Systemic lupus erythematosus,
inammasome activity inammatory cytokines, contributing to type 1 diabetes
autoimmunity
uncontrolled activation of the inammasome, leading to increased secretion of IL-1β and IL-18,
potent pro-inammatory cytokines. This dysregulation underlies cryopyrin-associated periodic
syndromes (CAPS), characterized by recurrent systemic inammation (Chen et al., 2023).
GOF mutations also affect immune regulation at the cellular level. For example, although FOXP3
is typically associated with regulatory T-cell function, certain rare GOF variants may paradoxically
impair immune balance, contributing to immune dysregulation syndromes. Additionally, CARD11
GOF mutations, which affect NF-κB activation, promote hyperactivation of B and T lymphocytes,
leading to autoimmune lymphoproliferative phenotypes and chronic immune overactivity (Snow
etal., 2012).
The pathogenic consequences of GOF mutations are often severe. Affected individuals may
exhibit early disease onset, multi-organ involvement, and poor response to conventional treatment.
However, targeted therapies that modulate the dysregulated pathways are being developed. For
instance, JAK inhibitors like tofacitinib and ruxolitinib have shown efcacy in patients with STAT3
GOF mutations, while IL-1 inhibitors such as anakinra are used to reduce inammation in NLRP3related diseases.
Table 2.9 provides examples of GOF mutations associated with autoimmune and autoinamma-
tory diseases, summarizing their effects and therapeutic implications.
2.6 LOSS-OF-FUNCTION MUTATIONS
A LOF mutation refers to a genetic alteration that reduces or abolishes the normal activity of a gene.
These mutations may arise through various mechanisms, including nonsense mutations (introducing premature stop codons), frameshift mutations (altering the reading frame), splice-site mutations
(disrupting RNA processing), and large deletions or structural rearrangements (removing essential
gene sequences). While LOF mutations are typically recessive, requiring both alleles to be affected
for a phenotype to manifest, some cases exhibit haploinsufciency, where a single functional copy
is insufcient to maintain normal biological activity.
In the context of autoimmune diseases, LOF mutations are often implicated in the failure of
immune tolerance mechanisms that normally prevent the immune system from attacking selftissues. One of the most well-documented examples is the AIRE gene, which governs the expression of peripheral tissue antigens in the thymus to mediate negative selection of autoreactive T cells.
LOF mutations in AIRE allow autoreactive cells to escape deletion, resulting in APECED, a condition characterized by multi-organ autoimmunity (Anderson & Su, 2016).
Another prominent LOF mutation involves the FOXP3 gene, which encodes a transcription factor critical for the function of regulatory T cells (Tregs). Mutations that inactivate FOXP3 disrupt
60 Bioinformatics of Autoimmune Diseases
TABLE 2.10
Example of Loss-of-Function Mutations and Their Impacts
Gene Mutation Description Impact
PTPN22 Single nucleotide Alters T-cell receptor signaling,
polymorphism (C1858T) increasing autoimmunity risk
resulting in R620W
substitution
SIAE Various missense mutations Impairs regulation of B-cell
leading to defective enzyme receptor signaling, contributing to
function loss of immune tolerance
LRBA Biallelic loss-of-function Disrupts CTLA4 function,
mutations causing protein resulting in immune
deciency dysregulation
CTLA4 Haploinsufciency due to Leads to reduced inhibitory
heterozygous mutations signaling in T cells, causing
excessive immune responses
SAT1 Loss-of-function mutations Associated with decreased
resulting in enzyme inactivity polyamine metabolism, linked to
autoimmunity
Associated Autoimmune Disease(s)
Type 1 diabetes, rheumatoid arthritis,
systemic lupus erythematosus, Graves’
disease, myasthenia gravis
Rheumatoid arthritis, type 1 diabetes,
multiple sclerosis, systemic lupus
erythematosus
Autoimmune enteropathy, immune
dysregulation syndrome
Autoimmune lymphoproliferative
syndrome, rheumatoid arthritis,
multiple sclerosis
Childhood-onset systemic lupus
erythematosus
Treg-mediated immune suppression and result in immune dysregulation, polyendocrinopathy,
enteropathy, X-linked (IPEX) syndrome, a severe early-onset autoimmune disorder marked by T1D,
enteropathy, and dermatitis (Bennett etal., 2001).
CTLA4, a key immune checkpoint molecule that downregulates T-cell activation, is also subject
to LOF mutations. Defective CTLA4 expression or signaling leads to sustained T-cell activation and
contributes to autoimmune diseases such as RA, SLE, and T1D (Schubert etal., 2014). Similarly,
LOF mutations in TNFAIP3 (A20), an inhibitor of NF-κB signaling, prevent the proper resolution
of inammatory responses, predisposing individuals to chronic inammation and diseases like SLE
and RA (Zhou etal., 2016).
LOF mutations also impact cytokine signaling pathways. Mutations in IL10RA and IL10RB
compromise anti-inammatory IL-10 signaling, leading to early-onset IBD due to unchecked intes-
tinal inammation (Glocker et al., 2009). Meanwhile, TYK2 LOF mutations, which impair type I
interferon and IL-12 signaling, increase susceptibility to infections as well as autoimmune diseases,
including lupus and MS (Boisson-Dupuis et al., 2018).
These genetic defects disrupt immune regulation and tolerance, resulting in persistent inammation and chronic autoimmune pathology. Insights into LOF mutations have driven the development
of targeted immunotherapies. For instance, abatacept, a CTLA4-Ig fusion protein, restores inhibitory signaling in T cells, while low-dose IL-2 therapy is being investigated to enhance Treg activity
in conditions involving FOXP3 deciency.
Table 2.10 summarizes notable LOF mutations associated with various autoimmune diseases and
their clinical implications.
2.7 SUMMARY
This chapter offers a comprehensive examination of the genetic and epigenetic alterations that
underlie the development, progression, and clinical variability of autoimmune diseases. Building on
the foundational concepts of immune dysregulation presented earlier, it shifts focus to the specic
gene variants and mutation types that shape immune responses at both the molecular and cellular
levels.
61 Genetic Markers in Autoimmunity
A central focus is placed on allelic variations and their role in genetic predisposition to autoimmunity. Among these, the HLA region emerges as the most critical, particularly HLA-DR and
HLA-DQ alleles. Variations in these genes modify the structure of the MHC molecules, especially
the peptide-binding grooves, thereby altering antigen presentation. These structural shifts enable
autoreactive T cells to escape deletion during central tolerance, a failure that contributes to diseases such as RA and celiac disease. In addition to HLA-associated risks, a growing number of
non-HLA gene variants also contribute to autoimmune susceptibility. Notable among these are
PTPN22, STAT4, IL2RA, and IRF5, each involved in regulating T-cell signaling, differentiation of
Th1 and Th17 subsets, and type I interferon pathways. The contribution of these non-HLA variants
is often polygenic and epistatic, meaning their combined effects can amplify immune dysregulation
in complex ways.
The discussion then turns to the specic types of genetic mutations implicated in autoimmunity.
SNP are the most prevalent and widely investigated, with well-documented examples like PTPN22
R620W and IL23R rs11209026. These variants affect T-cell activation, cytokine signaling, and the
balance between effector and regulatory immune functions. Other important SNPs occur in genes
such as IL-10, TNF, and STAT4, which are central to inammatory control. Insertion and deletion mutations (indels) represent another class of impactful alterations. These changes can lead to
frameshift mutations or premature stop codons, thereby disrupting protein function. For instance,
the NOD2 1007fs mutation is closely associated with Crohn’s disease and impairs bacterial recognition, while deletions in CTLA4 and LCE3B/C genes contribute to immune checkpoint failure and
epithelial barrier dysfunction. CNVs, which involve the gain or loss of larger DNA segments, also
play an important role. Deletions of genes like C4A and FCGR3B interfere with immune complex
clearance mechanisms, a hallmark of SLE. Conversely, gene duplications such as those affecting
DEFB4 can heighten antimicrobial peptide production, fueling inammation in conditions like psoriasis. Splicing mutations, which affect RNA processing, also contribute to autoimmunity. These
mutations can cause exon skipping or intron retention, altering protein synthesis. Mutations in genes
like FOXP3 and AIRE undermine the development and function of regulatory T cells and the establishment of central tolerance, giving rise to disorders such as IPEX and APECED.
The chapter next addresses the role of epigenetics in modulating autoimmune risk. Epigenetic
modications do not alter DNA sequences but inuence gene expression patterns in ways that link
environmental exposures with genetic susceptibility. DNA hypomethylation in genes such as CD40L,
TNF-α, and IL-6 leads to increased expression of pro-inammatory mediators. Modications to
histone proteins, including changes in acetylation patterns, alter chromatin accessibility and impact
immune regulation, particularly in diseases such as MS and IBD. In addition, ncRNAs (especially
miRNAs like miR-146a and miR-155) act as important post-transcriptional regulators of inammation. Dysregulation of these molecules has been documented across various autoimmune phenotypes. These epigenetic signatures not only help rene our understanding of disease mechanisms
but also open up potential avenues for therapeutic intervention, including the use of HDAC inhibitors, DNA methylation modulators, and miRNA-based therapies.
Larger-scale genomic alterations, known as SVs, are also examined for their contribution to autoimmune pathogenesis. These include deletions, duplications, inversions, and chromosomal translocations that can signicantly alter gene dosage or disrupt regulatory regions. Structural changes
in key loci such as HLA-DRB1, TNFAIP3 (which encodes A20), and CTLA4 have been linked to
impaired immune regulation. For example, deletion of TNFAIP3 removes a vital brake on NF-κB
signaling, resulting in persistent inammation characteristic of RA, SLE, and MS. Likewise,
CTLA4 deletions compromise immune checkpoints, contributing to unchecked T-cell activation
and syndromes like ALPS.
A nal classication presented in this chapter organizes mutations by their functional effects,
distinguishing between GOF and LOF mutations. GOF mutations enhance or introduce novel protein activities. For example, mutations in STAT3, NOD2, and NLRP1 heighten cytokine signaling
or inammasome activation, driving severe, often early-onset autoimmune syndromes. In contrast,
62 Bioinformatics of Autoimmune Diseases
FIGURE 2.5 Genomic and epigenetic changes implicated in autoimmune diseases.
LOF mutations impair essential immune functions. Mutations in AIRE and FOXP3 eliminate central and peripheral tolerance mechanisms, respectively, while mutations in CTLA4 and TNFAIP3
prevent the negative regulation of T-cell responses and inammatory signaling. Understanding
these functional categories has direct therapeutic relevance, particularly in the design of drugs that
aim to restore immune tolerance or suppress hyperinammatory cascades.
Figure 2.5 visually summarizes the genetic landscape of autoimmune diseases. At the center lies
the concept of “Genomic Autoimmune Diseases”, with ve major contributing categories radiating outward: mutations (including SNPs, Indels, CNVs, and splicing mutations), epigenetic mutations, SVs, GOF mutations, and LOF mutations. Connecting arrows depict the diverse molecular
mechanisms through which these alterations impair immune regulation and promote disease. This
integrated view highlights the complexity of autoimmune disorders and the multifaceted nature of
their genomic and epigenomic origins.
BIBLIOGRAPHY
Aitman, T. J., Dong, R., Vyse, T. J., Norsworthy, P. J., Johnson, M. D., Smith, J., … Cook, H. T. (2006).
Copy number polymorphism in Fcgr3 predisposes to glomerulonephritis in rats and humans. Nature,
439(7078), 851–855. https://doi.org/10.1038/nature04489
Anderson, M. S., & Su, M. A. (2016). AIRE expands: New roles in immune tolerance and beyond. Nature
Reviews Immunology, 16(4), 247–258. https://doi.org/10.1038/nri.2016.9
Bennett, C. L., Christie, J., Ramsdell, F., Brunkow, M. E., Ferguson, P. J., Whitesell, L., … Ochs, H. D. (2001).
The immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome (IPEX) is caused by
mutations of FOXP3. Nature Genetics, 27(1), 20–21. https://doi.org /10.1038/83713
Bluestone, J. A., Bour-Jordan, H., Cheng, M., & Anderson, M. (2015). T cells in the control of organ-specic
autoimmunity. Journal of Clinical Investigation, 125(6), 2250–2260. https://doi.org/10.1172/JCI80012
Boisson-Dupuis, S., Ramirez-Alejo, N., Li, Z., Patin, E., Rao, G., Kerner, G., … Casanova, J. L. (2018).
Tuberculosis and impaired IL-23–dependent IFN-γ immunity in humans homozygous for a common
TYK2 missense variant. Science Immunology, 3(30), eaau8714. https://doi.org/10.1126/sciimmunol.
aau8714
Bottini, N., Musumeci, L., Alonso, A., Rahmouni, S., Nika, K., Rostamkhani, M., … Mustelin, T. (2004). A
functional variant of lymphoid tyrosine phosphatase is associated with type I diabetes. Nature Genetics,
36(4), 337–338. https://doi.org/10.1038/ng1323
63 Genetic Markers in Autoimmunity
Chen, S., Sun, B., Hao, R., Xu, H., Zhang, J., & Chen, Y. (2023). The NLRP3 inammasome: Contributions to
inammation and mechanisms of disease. Cellular & Molecular Biology Letters, 28, 23. https://doi.org/
10.1186/s11658-023-00462-9
Coit, P., Jeffries, M., Altorok, N., Dozmorov, M. G., Koelsch, K. A., Wren, J. D., & Sawalha, A. H. (2013).
Genome-wide DNA methylation study suggests epigenetic accessibility and transcriptional poising of
interferon-regulated genes in naive CD4+ T cells from lupus patients. Journal of Autoimmunity, 43,
78–84. https://doi.org/10.1016/j.jaut.2013.04.003
Cooper, G. M., & Hausman, R. E. (2013). The cell: A molecular approach (6th ed.). Sinauer Associates.
Danese, S., Vuitton, L., & Peyrin-Biroulet, L. (2015). Biologic agents for IBD: Practical insights.
Nature Reviews Gastroenterology & Hepatology, 12(9), 537–545. https://doi.org/10.1038/nrgastro.
2015.135
de Cid, R., Riveira-Munoz, E., Zeeuwen, P. L., Robarge, J., Liao, W., Dannhauser, E. N., …, & Coto, E. (2009).
Deletion of the late cornied envelope LCE3B and LCE3C genes as a susceptibility factor for psoriasis.
Nature Genetics, 41(2), 211–215. https://doi.org/10.1038/ng.313
Dendrou, C. A., Cortes, A., Shipman, L., Evans, H. G., Atteld, K. E., Jostins, L., Barber, T., Kaur, G., &
Fugger, L. (2016). Resolving TYK2 locus genotype-to-phenotype differences in autoimmunity. Science
Translational Medicine, 8(363), 363ra149. https://doi.org/10.1126/scitranslmed.aag1974
Duerr, R. H., Taylor, K. D., Brant, S. R., Rioux, J. D., Silverberg, M. S., Daly, M. J., … Cho, J. H. (2006).
A genome-wide association study identies IL23R as an inammatory bowel disease gene. Science,
314(5804), 1461–1463. ht t ps://doi.org /10.1126/science.1135245
Feinberg, A. P. (2018). The key role of epigenetics in human disease prevention and mitigation. New England
Journal of Medicine, 378(14), 1323–1334. https://doi.org/10.1056/NEJMra1402513
Furie, R., Khamashta, M., Merrill, J. T., Werth, V. P., Kalunian, K., Brohawn, P., Illei, G. G., Drappa, J., Wang,
L., Yoo, S., & Kinaszczuk, M. (2020). Anifrolumab, an anti–interferon-α receptor monoclonal anti-
body, in moderate-to-severe systemic lupus erythematosus. New England Journal of Medicine, 382(3),
211–221. htt ps://doi.org /10.1056/NEJMoa1912196
Glocker, E. O., Kotlarz, D., Boztug, K., Gertz, E. M., Schäffer, A. A., Noyan, F., … Klein, C. (2009).
Inammatory bowel disease and mutations affecting the interleukin-10 receptor. New England Journal
of Medicine, 361(21), 2033–2045. https://doi.org/10.1056/NEJMoa0907206
Graham, R. R., Kozyrev, S. V., Baechler, E. C., Reddy, M. V., Plenge, R. M., Bauer, J. W., Ortmann, W. A.,
Koeuth, T., Gonzalez Escribano, M. F., Pons-Estel, B., Petri, M., Daly, M., Gregersen, P. K., Alarcón-
Riquelme, M. E., & Behrens, T. W. (2006). A common haplotype of interferon regulatory factor 5
(IRF5) regulates splicing and expression and is associated with increased risk of systemic lupus erythe-
matosus. Nature Genetics, 38(5), 550–555. https://doi.org/10.1038/ng1782
Haapaniemi, E. M., Kaustio, M., Rajala, H. L., Järvinen, P., Ahlfors, H., Das Roy, R., … Mustjoki, S. (2015).
Autoimmunity, hypogammaglobulinemia, lymphoproliferation, and mycobacterial disease in patients
with activating mutations in STAT3. Blood, 125(4), 639–648. https://doi.org/10.1182/blood-2014-
04-570101
Hollox, E. J., Huffmeier, U., Zeeuwen, P. L., Palla, R., Lascorz, J., Rodijk-Olthuis, D., … Armour, J. A.
(2008). Psoriasis is associated with increased beta-defensin genomic copy number. Nature Genetics,
40(1), 23–25. https://doi.org/10.1038/ng.2007.48
Hugot, J. P., Chamaillard, M., Zouali, H., Lesage, S., Cézard, J. P., Belaiche, J., … Thomas, G. (2001).
Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn’s disease. Nature,
411(6837), 599– 603. https://doi.org/10.1038/35079107
Karban, A. S., Okazaki, T., Panhuysen, C. I., Gallegos, T., Potter, J. J., Bailey-Wilson, J. E., …, & Brant, S. R.
(2004). Functional annotation of a novel NFKB1 promoter polymorphism that increases risk for ulcer-
ative colitis. Human Molecular Genetics, 13(1), 35–45. https://doi.org/10.1093/hmg/ddh008
Lesage, S., Zouali, H., Cézard, J. P., Colombel, J. F., Belaiche, J., Almer, S., Tysk, C., O’Morain, C., Gassull,
M., Binder, V., Finkel, Y., Modigliani, R., Gower-Rousseau, C., Macry, J., Merlin, F., Chamaillard,
M., Jannot, A. S., Thomas, G., & Hugot, J. P.; EPWG-IBD Group; EPIMAD Group; GETAID Group.
(2002). CARD15/NOD2 mutational analysis and genotype–phenotype correlation in 612 patients
with inammatory bowel disease. American Journal of Human Genetics, 70(4), 845–857. https://doi.
org/10.1086/339432
Lu, Q., Wu, A., Tesmer, L., Ray, D., Yousif, N., & Richardson, B. (2007). Demethylation of CD40LG on the
inactive X in T cells from women with lupus. Journal of Immunology, 179(9), 6352–6358. https://doi.
org/10.4049/jimmunol.179.9.6352
Соседние файлы в папке Библиотека им академика М.И. Перельмана